Salivary gland malignancy and radioiodine therapy for thyroid cancer

Thyroid

Volumn 20, Issue 6, 2010, Pages 647-651

  Klubo Gwiezdzinska, Joanna ^a   Van Nostrand, Douglas ^a   Burman, Kenneth D ^a   Vasko, Vasyl ^b   Chia, Stanley ^a   Deng, Tom ^a   Kulkarni, Kanchan ^a   Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GOITER; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOCYTOMA; PAROTID GLAND CANCER; PAROTIDECTOMY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIATION INJURY; SALIVARY GLAND BIOPSY; SECOND CANCER; THYROID PAPILLARY CARCINOMA; WHOLE BODY SCINTISCANNING; DRUG EFFECTS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RADIATION INDUCED NEOPLASM; RADIATION RESPONSE; SALIVARY GLAND; SALIVARY GLAND NEOPLASMS; THYROID NEOPLASMS;

FEMALE; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; THYROID NEOPLASMS;

EID: 77953917877     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0466     Document Type: Article

References (36)

1. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515.
2. Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, Tennvall J, Wicklund H, Boice JD Jr. 1991 Cancer risks in thyroid cancer patients. Br J Cancer 64:159-163.
3. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L 1995 Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36:21-27.
4. Rubino C, De Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644.
5. Verkooijen RB, Smit JW, Romijn JA, Stokkel MP 2006 The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155:801-806.
6. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Sallé F, Mahoudeau J, Bardet S 2004 Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31:685-691
7. Bhattacharyya N, Chien W 2006 Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 115: 607-610.
8. De Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, De la Genardiére E, Meunier F, Parmentier C, Hill C, Sancho-Garnier H 1997 Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 75:734-739.
9. Nio Y, Iguchi C, Itakura M, Toga T, Hashimoto K, Koike M, Omori H, Sato Y, Endo S 2009 High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res 29:1607-1610.
10. Bonacci R, Pinchera A, Fierabracci P, Gigliotti A, Grasso L, Giani C 1996 Relevance of estrogen and progesterone re- ceptors enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue. J Endocrinol Invest 19: 159-164.
11. Shering SG, Zbar AP, Moriarty M, McDermott EW, O'Higgins NJ, Smyth PP 1996 Thyroid disorders and breast cancer. Eur J Cancer Prev 5:504-506.
12. Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS 1999 Incidence of breast carcinoma in women with thyroid carcinoma. Cancer 85:696-705.
13. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451-457.
14. Van Nostrand D, Freitas J 2006 Side effects of 131-I for ablation and treatment of well differentiated thyroid carcinoma. In: Wartofsky L, Van Nostrand D (eds) Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd edition. Humana Press, Totowa, NJ, pp 459-484.
15. Mandel SJ, Mandel L 2003 Radioactive iodine and the salivary glands. Thyroid 13:265-271.
16. Newkirk KA, Ringel MD, Wartofsky L, Burman KD 2000 The role of radioactive iodine in salivary gland dysfunction. Ear Nose Throat J 49:460-468.
17. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
18. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Sallé F, Mahoudeau J, Bardet S 2004 Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31:685-691.
19. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
20. Wartofsky L 2009 Highlights of the American Thyroid Association guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: the 2009 revision. Thyroid 19:1139-1143.
21. Mandel L, Liu F 2007 Salivary gland injury resulting from exposure to radioactive iodine: case reports. J Am Dent Assoc 138:1582-1587.
22. Kloos RT 2009 Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid 19:925-928.
23. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S 2005 Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46: 261-266.
24. Van Nostrand D, Atkins F, Bandaru VV, Chennupati SP, Moreau S, Burman K, Wartofsky L 2009 Salivary gland protection with sialagogues: a case study. Thyroid 19:1005-1008.
25. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M 1998 Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 16:3542-3549.
26. Mendoza A, Shaffer B, Karakla D, Mason ME, Elkins D, Goffman TE 2004 Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid 14:133-140.
27. Kim SJ, Choi HY, Kim IJ, Kim YK, Jun S, Nam HY, Kim JS 2008 Limited cytoprotective effects of amifostine in highdose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid 18:325-331.
28. Olsen KD, Lewis JE 2001 Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck 23:705-712.
29. Soares AB, Juliano PB, Araujo VC, Metze K, Altemani A 2007 Angiogenic switch during tumor progression of carcinoma ex-pleomorphic adenoma. Virchows Arch 451:65-71.
30. Bhattacharyya N, Fried MP 2005 Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol 26:39-44.
31. McHugh JB, Visscher DW, Barnes EL 2009 Update on selected salivary gland neoplasms. Arch Pathol Lab Med 133:1763-1774.
32. Lewis JE, Olsen KD, Sebo TJ 2001 Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32:596-604.
33. Rodríguez-Fernández J, Mateos-Micas M, Martínez- Tello FJ, Berjón J, Montalvo JJ, Forteza-González G, Galan-Hernández R 2008 Metastatic benign pleomorphic adenoma. Report of a case and review of the literature. Med Oral Patol Oral Cir Bucal 13:193-196
34. Chen AM, Garcia J, Lee NY, Bucci MK, Eisele DW 2007 Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? Int J Radiat Oncol Biol Phys Mar 67:988-994.
35. Chen AM, Garcia J, Bucci MK, Quivey JM, Eisele DW 2006 Recurrent pleomorphic adenoma of the parotid gland: longterm outcome of patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 66:1031-1035. (Pubitemid 44633509)
36. Chen AM, Garcia J, Bucci MK, Quivey JM, Eisele DW 2007 The role of postoperative radiation therapy in carcinoma ex pleomorphic adenoma of the parotid gland. Int J Radiat Oncol Biol Phys 67:138-143.